UPL is currently trading at Rs. 756.20, up by 8.90 points or 1.19% from its previous closing of Rs. 747.30 on the BSE.
The scrip opened at Rs. 748.00 and has touched a high and low of Rs. 762.70 and Rs. 746.60 respectively. So far 32737 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 864.75 on 08-Jun-2021 and a 52 week low of Rs. 625.00 on 24-Feb-2022.
Last one week high and low of the scrip stood at Rs. 814.90 and Rs. 733.25 respectively. The current market cap of the company is Rs. 56933.59 crore.
The promoters holding in the company stood at 28.45%, while Institutions and Non-Institutions held 53.10% and 10.72% respectively.
UPL has entered into new supply agreement for ‘Spirotetramat’, an insecticide created and developed by Bayer for integrated pest control. The agreement reflects UPL’s OpenAg purpose and commitment to open industry collaboration.
Through this long-term global data access and supply agreement, UPL will use its expertise in insecticides and global research and development network to develop, register and distribute new differentiated solutions containing Spirotetramat, that address farmer needs specifically around resistance management and/or hard-to-control sucking pests. This new supply agreement builds on existing license agreements between UPL and Bayer covering a range of agricultural solutions.
UPL is global player of crop protection products has customer base in 123 countries. It has subsidiary offices in Argentina, Australia, Bangladesh, Brazil, China, Canada, Denmark, Indonesia, France, Hong Kong, Japan, Korea, Mauritius, Mexico, New Zealand, Russia, Spain, Taiwan, South Africa, USA, UK, Vietnam and Zambia.
| Company Name | CMP |
|---|---|
| UPL | 657.55 |
| PI Industries | 3054.10 |
| Bayer CropScience | 4835.00 |
| Sharda Cropchem | 1103.90 |
| Sumitomo Chemical | 443.85 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: